ICM
APLS

III Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

III Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,019
Closed -$169K – 50
2019
Q3 		$169K Buy
+7,019
New +$193K 0.08% 42

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

III Capital Management's APLS Position: Q4 2019 in Review

III Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2019, closing a stake of 7,019 shares — an estimated $169K sold.

III Capital Management first reported a position in APLS in Q3 2019 and held it in 1 quarter. The position peaked at $169K in Q3 2019. 133 funds tracked by Wall St. Rank hold APLS as of Q4 2019.

  • III Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • III Capital Management sold 7,019 Apellis Pharmaceuticals shares in Q4 2019, an estimated $169K.
  • III Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • III Capital Management's Apellis Pharmaceuticals position peaked at $169K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2019.

Based on III Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.